

SUMMARY OF PRODUCT CHARACTERISTICS
MYLTEGA DT
(Dolutegravir Dispersible Tablets 10 mg)

1. NAME OF THE MEDICINAL PRODUCT

Dolutegravir Dispersible Tablets 10 mg

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains Dolutegravir Sodium equivalent to Dolutegravir 10 mg .

3. PHARMACEUTICAL FORM

Film-coated Tablet.

A pink colored, film-coated, Oval shape, biconvex tablet debossed with **D** on the left side and **T** on the right side of the score line on one side and **M** on the left side of the score line on other side.

The tablet can be divided into two equal halves.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Dolutegravir Dispersible Tablets 10 mg are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg [see 5.1]

4.2 Posology and method of administration

Dolutegravir Dispersible Tablets 10 mg should be prescribed by physicians experienced in the management of HIV infection.

Posology

Pediatric Patients: Treatment-naïve or treatment-experienced INSTI-naïve patients aged at least 4 weeks and weighing at least 3 kg. See Tables 1,2 for complete pediatric dosing recommendations. (Dolutegravir 50mg tablets and Dolutegravir Dispersible Tablets 10 mg are not bioequivalent and are not interchangeable on a milligram-per-milligram basis.

General Dosing and Administration Instructions for Pediatric Patients

Do not interchange Dolutegravir 50mg tablets and Dolutegravir Dispersible Tablets 10 mg tablets for oral suspension on a milligram-per-milligram basis due to differing pharmacokinetic profiles [see (4.4), 5.2)]. If switching from the tablets to the tablets for oral suspension, follow the recommended dosage in Table 1. If switching from the tablets for oral suspension to the tablets, follow the recommended dosage in Table 2. See administration instructions in *Dosage and Administration*

Recommended Dosage in Pediatric Patients Weighing 3 to 19.9 kg

The recommended weight-based dosage of Dolutegravir Dispersible Tablets 10 mg tablets for oral suspension in **pediatric patients weighing 3 to 19.9 kg** (4 weeks and older, treatment-naïve or treatment-experienced but naïve to INSTI treatment) is described in Table 1.

Do not use Dolutegravir 50mg tablets in patients weighing 3 to 19.9 kg. See administration instructions in *Dosage and Administration*.

Table 1. Recommended Dosage of Dolutegravir Dispersible Tablets 10 mg in Pediatric Patients 4 Weeks and Older Weighing 3 to 19.9 kg

| Body Weight | Dolutegravir Dispersible Tablets 10 mg Number of Tablets |
|----------------------------|---|
| 3–5.9 kg | 0.5 |
| 6–9.9 kg | 1.5 |
| 10–14.9 kg | 2 |
| 15 kg to less than 19.9 kg | 2.5 |

If certain UGT1A or CYP3A inducers are coadministered, then administer Dolutegravir Dispersible Tablets 10 mg twice daily [see 4.5].

Recommended Dosage in Pediatric Patients Weighing 20 kg or Greater

For **pediatric patients weighing 20 kg or greater** (4 weeks and older, treatment-naïve or treatment-experienced but naïve to INSTI treatment) administer either:

- Dolutegravir Dispersible Tablets 10 mg tablets for oral suspension (preferred in pediatric patients weighing less than 20 kg) (Table 1), or
- Dolutegravir 50mg tablets for oral use (Table 2)

Table 2. Recommended Dosage of Dolutegravir 50mg tablets Tablets in Pediatric Patients Weighing 20 kg or Greater

| Body Weight | Dolutegravir 50mg tablets Number of Tablets |
|-------------|--|
| 20–24.9 kg | 1 x 50-mg |
| 25–29.9 kg | 1 x 50-mg |
| ≥30 kg | 1 x 50-mg |

If certain UGT1A or CYP3A inducers are coadministered, then administer Dolutegravir 50mg tablets twice daily [see 4.5].

Hepatic Impairment

No clinically important pharmacokinetic differences between subjects with moderate hepatic impairment and matching healthy subjects were observed. No dosage adjustment is necessary for patients with mild to

moderate hepatic impairment (Child-Pugh Score A or B). The effect of severe hepatic impairment (Child-Pugh Score C) on the pharmacokinetics of dolutegravir has not been studied. Therefore, Dolutegravir 50mg tablets and Dolutegravir Dispersible Tablets 10 mg are not recommended for use in patients with severe hepatic impairment [see 5.2].

Renal Impairment

Dolutegravir plasma concentrations were decreased in subjects with severe renal impairment compared with those in matched healthy controls. However, no dosage adjustment is necessary for treatment-naïve or treatment-experienced and INSTI-naïve patients with mild, moderate, or severe renal impairment or for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance) with mild or moderate renal impairment. Caution is warranted for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance [see *Microbiology (12.4)*]) with severe renal impairment, as the decrease in dolutegravir concentrations may result in loss of therapeutic effect and development of resistance to Dolutegravir 50mg tablets, Dolutegravir Dispersible Tablets 10 mg, or other coadministered antiretroviral agents [see 5.2]. There is inadequate information to recommend appropriate dosing of dolutegravir in patients requiring dialysis.

Method of administration

- Administer Dolutegravir 50mg tablets and Dolutegravir Dispersible Tablets 10 mg tablets for oral suspension with or without food.
- The tablet can be divided into two equal halves.
- Do not chew or crush Dolutegravir dispersible tablets 10 mg.

Instruct patients (or instruct caregivers) to either:

- Swallow the dispersible tablet whole (if more than one tablet is required, swallow one tablet at a time to reduce the risk of choking), or Fully disperse the dispersible tablet in 5 mL of drinking water (if using ½ or 1½ dispersible tablet) or 10 mL (if using 2, 2 ½, or 3 dispersible tablet) Swirl or stir until the tablets disperse completely. After full dispersion, administer the oral suspension within 30 minutes of mixing.

4.3 Contraindications

Dolutegravir Dispersible Tablets 10 mg are contraindicated in patients:

- with previous hypersensitivity reaction to dolutegravir [see 4.4].
- receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events [see *Drug Interactions (4.5)*].
- Formulation contains mannitol which may have a mild laxative effect.

4.4 Special warnings and precautions for use

Hypersensitivity Reactions

Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury. The events were reported in less than 1% of subjects receiving Dolutegravir 50mg tablets in Phase 3 clinical trials. Discontinue Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters or peeling of the skin, oral blisters or lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema, difficulty breathing). Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated. Delay in stopping

treatment with Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg or other suspect agents after the onset of hypersensitivity may result in a life-threatening reaction. Dolutegravir 50mg tablets and Dolutegravir Dispersible Tablets 10 mg are contraindicated in patients who have experienced a previous hypersensitivity reaction to dolutegravir.

Hepatotoxicity

Hepatic adverse events have been reported in patients receiving a dolutegravir-containing regimen. Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg [see 4.8]. In some cases, the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn. Cases of hepatic toxicity, including elevated serum liver biochemistries, hepatitis, and acute liver failure have been reported in patients receiving a dolutegravir-containing regimen without pre-existing hepatic disease or other identifiable risk factors. Drug-induced liver injury leading to liver transplant has been reported with TRIUMEQ (abacavir, dolutegravir, and lamivudine). Monitoring for hepatotoxicity is recommended.

Embryo-Fetal Toxicity

An observational study showed an association between Dolutegravir 50mg tablets and an increased risk of neural tube defects when Dolutegravir 50mg tablets was administered at the time of conception and in early pregnancy. As there is limited understanding of reported types of neural tube defects associated with dolutegravir use and because the date of conception may not be determined with precision, an alternative treatment to Dolutegravir 50mg tablets should be considered at the time of conception through the first trimester of pregnancy [see 4.6].

Perform pregnancy testing before initiation of dolutegravir in adolescents and adults of childbearing potential to exclude use of dolutegravir during the first trimester of pregnancy [see 4.2]. Initiation of dolutegravir is not recommended in adolescents and adults actively trying to become pregnant unless there is no suitable alternative [see sec4.6].

Counsel adolescents and adults of childbearing potential to consistently use effective contraception [see 4.6].

In adolescents and adults of childbearing potential currently on dolutegravir who are actively trying to become pregnant, or if pregnancy is confirmed in the first trimester, assess the risks and benefits of continuing dolutegravir versus switching to another antiretroviral regimen and consider switching to an alternative regimen [see 4.6].

Dolutegravir may be considered during the second and third trimesters of pregnancy if the expected benefit justifies the potential risk to the pregnant woman and the fetus.

Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions

The concomitant use of Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg and other drugs may result in known or potentially significant drug interactions, some of which may lead to [see 4.3], *Drug Interactions 4.5*]:

- Loss of therapeutic effect of Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg and possible development of resistance.
- Possible clinically significant adverse reactions from greater exposures of concomitant drugs.

For concomitant drugs for which the interaction can be mitigated, please see Table 3 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during therapy with Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg ; review concomitant medications during therapy with Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg ; and monitor for the adverse reactions associated with the concomitant drugs.

Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg . During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jirovecii* pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.

Different Formulations Are Not Interchangeable

Dolutegravir 50mg tablets and Dolutegravir Dispersible Tablets 10 mg are not bioequivalent and are not interchangeable on a milligram-per-milligram basis [see 5.2]. If a pediatric patient switches from one formulation to the other, the dose must be adjusted for the new dosage formulation [see 4.2]]. Incorrect dosing of a given formulation may result in underdosing and loss of therapeutic effect and possible development of resistance or possible clinically significant adverse reactions from greater exposure of dolutegravir.

4.5 Interaction with other medicinal products and other forms of interaction

Effect of Dolutegravir on the Pharmacokinetics of Other Agents

In vitro, dolutegravir inhibited the renal organic cation transporters, OCT2 ($IC_{50} = 1.93$ microM) and multidrug and toxin extrusion transporter (MATE) 1 ($IC_{50} = 6.34$ microM). In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1. Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin, Table 3) [see Contraindications (4), D

In vitro, dolutegravir inhibited the basolateral renal transporters, organic anion transporter (OAT) 1 ($IC_{50} = 2.12$ microM) and OAT3 ($IC_{50} = 1.97$ microM). However, in vivo, dolutegravir did not alter the plasma concentrations of tenofovir or para-amino hippurate, substrates of OAT1 and OAT3.

In vitro, dolutegravir did not inhibit (IC_{50} greater than 50 microM) the following: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, UGT1A1, UGT2B7, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile salt export pump (BSEP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT1, multidrug resistance protein (MRP)2, or MRP4. In vitro, dolutegravir did not induce CYP1A2, CYP2B6, or CYP3A4. Based on these data and the results of drug interaction trials, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters.

Effect of Other Agents on the Pharmacokinetics of Dolutegravir

Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A. Dolutegravir is also a substrate of UGT1A3, UGT1A9, BCRP, and P-gp in vitro. Drugs that induce those enzymes and transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir.

Coadministration of dolutegravir and other drugs that inhibit these enzymes may increase dolutegravir plasma concentration.

Etravirine significantly reduced plasma concentrations of dolutegravir, but the effect of etravirine was mitigated by coadministration of lopinavir/ritonavir or darunavir/ritonavir and is expected to be mitigated by atazanavir/ritonavir (Table 3) 5.2].

In vitro, dolutegravir was not a substrate of OATP1B1 or OATP1B3.

Established and Other Potentially Significant Drug Interactions

Table 3 provides clinical recommendations as a result of drug interactions with Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg . These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of efficacy [see 4.2, 5.2.]

Table 3. Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Trials or Predicted Interactions [see Dosage and Administration (4.2)]

| Concomitant Drug Class: Drug Name | Effect on Concentration of Dolutegravir and/or Concomitant Drug | Clinical Comment |
|--|---|--|
| HIV-1 Antiviral Agents | | |
| Non-nucleoside reverse transcriptase inhibitor: Etravirine ^a | ↓Dolutegravir | Use of Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended. |
| Non-nucleoside reverse transcriptase inhibitor: Efavirenz ^a | ↓Dolutegravir | Adjust dose of Dolutegravir 50mg tablets to twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg to twice daily (Tables 2, 3, and 4). Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance. ^b |
| Non-nucleoside reverse transcriptase inhibitor: Nevirapine | ↓Dolutegravir | Avoid coadministration with nevirapine because there are insufficient data to make dosing recommendations. |
| Protease inhibitors: Fosamprenavir/ritonavir ^a Tipranavir/ritonavir ^a | ↓Dolutegravir | Adjust dose of Dolutegravir 50mg tablets to twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg to twice daily (Tables 2, 3, and 4). Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance |

| | | |
|--|----------------|--|
| | | substitutions or clinically suspected INSTI resistance. ^b |
| Other Agents | | |
| Dofetilide | ↑Dofetilide | Coadministration is contraindicated with Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg [see 4.3]. |
| Carbamazepine ^a | ↓Dolutegravir | Adjust dose of Dolutegravir 50mg tablets to twice daily in treatment-naïve or treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg to twice daily (Tables 1,2). Use alternative treatment that does not include carbamazepine where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance. ^b |
| Oxcarbazepine Phenytoin Phenobarbital St. John's wort (<i>Hypericum perforatum</i>) | ↓Dolutegravir | Avoid coadministration with Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg because there are insufficient data to make dosing recommendations. |
| Medications containing polyvalent cations (e.g., Mg or Al): Cation-containing antacids ^a or laxatives Sucralfate Buffered medications | ↓Dolutegravir | Administer Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg 2 hours before or 6 hours after taking medications containing polyvalent cations. |
| Oral calcium or iron supplements, including multivitamins containing calcium or iron^a | ↓Dolutegravir | When taken with food, Dolutegravir 50mg tablets and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron. |
| Potassium channel blocker: Dalfampridine | ↑Dalfampridine | Elevated levels of dalfampridine increase the risk of seizures. The potential benefits of taking dalfampridine concurrently with Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg should be considered against the risk of seizures in these patients. |
| Metformin | ↑Metformin | Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of Dolutegravir |

| | | |
|-----------------------|---------------|---|
| | | 50mg tablets or Dolutegravir Dispersible Tablets 10 mg and metformin. |
| Rifampin ^a | ↓Dolutegravir | Adjust dose of Dolutegravir 50mg tablets to twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg to twice daily (Tables 1,2). Use alternatives to rifampin where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance. ^b |

^a See 5.2 Table 11 or Table 12 for magnitude of interaction.

^b The lower dolutegravir exposures observed in INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance [see 5.1]) upon coadministration with certain inducers may result in loss of therapeutic effect and development of resistance to Dolutegravir 50mg tablets or other coadministered antiretroviral agents.

Drugs without Clinically Significant Interactions with Dolutegravir

Based on drug interaction trial results, the following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, daclatasvir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see 5.2].

4.6 Fertility, pregnancy and lactation

Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR).

Risk Summary

Data from a birth outcome surveillance study has identified an increased risk of neural tube defects when Dolutegravir 50mg tablets is administered at the time of conception compared with non-dolutegravir-containing antiretroviral regimens. As defects related to closure of the neural tube occur from conception through the first 6 weeks of gestation, embryos exposed to dolutegravir from the time of conception through the first 6 weeks of gestation are at potential risk. In addition, 2 of the 5 birth defects (encephalocele and iniencephaly), which have been observed with dolutegravir use, although often termed neural tube defects, may occur post-neural tube closure, the time period of which may be later than 6 weeks of gestation, but within the first trimester. Due to the limited understanding of the types of reported neural tube defects associated with dolutegravir use and because the date of conception may not be determined with precision, an alternative treatment to dolutegravir should be considered at the time of conception through the first trimester of pregnancy. Initiation of dolutegravir is not recommended in adolescents and adults actively trying to become pregnant unless there is no suitable alternative (see Data).

In adolescents and adults of childbearing potential currently on dolutegravir who are actively trying to become pregnant, or if pregnancy is confirmed in the first trimester, assess the risks and benefits of continuing dolutegravir versus switching to another antiretroviral regimen and consider switching to an alternative regimen. Advise pregnant adolescents and adults of the potential risk to the embryo exposed to dolutegravir from the time of conception through the first trimester of pregnancy. A benefit-risk assessment should consider factors such as feasibility of switching, tolerability, ability to maintain viral suppression, and risk of transmission to the infant against the risk of neural tube defects [see 4.4].

There are insufficient human data on the use of dolutegravir during pregnancy to definitively assess a drug-associated risk for birth defects and miscarriage. The background risk for major birth defects for the indicated population is unknown. In the U.S. general population, the estimated background rate for major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

In animal reproduction studies, no evidence of adverse developmental outcomes was observed with dolutegravir at systemic exposures (AUC) less than (rabbits) and approximately 27 times (rats) the exposure in humans at the maximum recommended human dose (MRHD) of Dolutegravir 50mg tablets (see Data).

Data

Human Data: In a birth outcome surveillance study in Botswana, there were 5 cases of neural tube defects reported out of 1,683 deliveries (0.3%) to women who were exposed to dolutegravir-containing regimens at the time of conception. In comparison, the neural tube defect prevalence rates were 0.1% (15/14,792 deliveries) in the non-dolutegravir arm and 0.08% (70/89,372 deliveries) in the HIV-uninfected arm. Five cases reported with dolutegravir included one case each of encephalocele, anencephaly, and iniencephaly, and 2 cases of myelomeningocele. In the same study, one infant out of 3,840 (0.03%) deliveries to women who started dolutegravir during pregnancy had a neural tube defect, compared with 3 infants out of 5,952 (0.05%) deliveries to women who started non-dolutegravir-containing regimens during pregnancy.

Data analyzed to date from other sources including the APR, clinical trials, and postmarketing data are insufficient to address the risk of neural tube defects with dolutegravir.

Data from the birth outcome surveillance study described above and postmarketing sources with more than 1,000 pregnancy outcomes from second and third trimester exposure in pregnant women indicate no evidence of increased risk of adverse birth outcomes.

Animal Data: Dolutegravir was administered orally at up to 1,000 mg per kg daily to pregnant rats and rabbits on Gestation Days 6 to 17 and 6 to 18, respectively, and to rats on Gestation Day 6 to Lactation/Postpartum Day 20. No adverse effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed at up to the highest dose tested. During organogenesis, systemic exposures (AUC) to dolutegravir in rabbits were less than the exposure in humans at the MRHD and in rats were approximately 27 times the exposure in humans at the MRHD. In the rat pre/postnatal development study, decreased body weight of the developing offspring was observed during lactation at a maternally toxic dose (approximately 27 times human exposure at the MRHD).

Lactation

Risk Summary

The Centers for Disease Control and Prevention recommends that HIV-1–infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection.

It is not known whether dolutegravir is present in human breast milk, affects human milk production, or has effects on the breastfed infant. When administered to lactating rats, dolutegravir was present in milk (see Data).

Because of the potential for (1) HIV-1 transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants), and (3) adverse reactions in a breastfed infant similar to those seen in adults, instruct mothers not to breastfeed if they are receiving dolutegravir.

Data

Animal Data: Dolutegravir was the primary drug-related component excreted into the milk of lactating rats following a single oral dose of 50 mg per kg on Lactation Day 10, with milk concentrations of up to approximately 1.3 times that of maternal plasma concentrations observed 8 hours postdose.

Females and Males of Reproductive Potential

Pregnancy Testing

Perform pregnancy testing in adolescents and adults of childbearing potential before initiation of dolutegravir.

Contraception

In adolescents and adults of childbearing potential currently on dolutegravir who are actively trying to become pregnant, or if pregnancy is confirmed in the first trimester, assess the risks and benefits of continuing dolutegravir versus switching to another antiretroviral regimen and consider switching to an alternative regimen [see 4.4].

Counsel adolescents and adults of childbearing potential who are taking dolutegravir to consistently use effective contraception.

4.7 Effects on ability to drive and use machines

Patients should be informed that dizziness has been reported during treatment with dolutegravir. The clinical status of the patient and the adverse reaction profile of dolutegravir should be borne in mind when considering the patient's ability to drive or operate machinery.

4.8 Undesirable effects

The following serious adverse drug reactions are discussed in other sections of the labeling:

- Hypersensitivity reactions [see *Warnings and Precautions* 4.4].
- Hepatotoxicity [see 4.4]
- Immune Reconstitution Syndrome [see 4.4].

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience in Adult Subjects

Treatment-Naïve Subjects: The safety assessment of Dolutegravir 50mg tablets in HIV-1–infected treatment-naïve subjects is based on the analyses of data from 2 international, multicenter, double-blind trials, SPRING-2 (ING113086) and SINGLE (ING114467) and data from the international, multicenter, open-label FLAMINGO (ING114915) trial.

In SPRING-2, 822 subjects were randomized and received at least 1 dose of either Dolutegravir 50mg tablets 50 mg once daily or raltegravir 400 mg twice daily, both in combination with fixed-dose dual nucleoside reverse transcriptase inhibitor (NRTI) treatment (either abacavir sulfate and lamivudine [EPZICOM] or emtricitabine/tenofovir [TRUVADA]). There were 808 subjects included in the efficacy and safety analyses. Through 96 weeks, the rate of adverse events leading to discontinuation was 2% in both treatment arms.

In SINGLE, 833 subjects were randomized and received at least 1 dose of either Dolutegravir 50mg tablets 50 mg with fixed-dose abacavir sulfate and lamivudine (EPZICOM) once daily or fixed-dose efavirenz/emtricitabine/tenofovir (ATRIPLA) once daily (study treatment was blinded through Week 96 and open-label from Week 96 through Week 144). Through 144 weeks, the rates of adverse events leading to discontinuation were 4% in subjects receiving Dolutegravir 50mg tablets once daily + EPZICOM and 14% in subjects receiving ATRIPLA once daily.

Treatment-emergent adverse reactions of moderate to severe intensity observed in at least 2% of subjects in either treatment arm in SPRING-2 and SINGLE trials are provided in Table 4. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.

Table 4. Treatment-Emergent Adverse Reactions of at Least Moderate Intensity (Grades 2 to 4) and at Least 2% Frequency in Treatment-Naïve Subjects in SPRING-2 (Week 96 Analysis) and SINGLE Trials (Week 144 Analysis)

| System Organ Class/ Preferred Term | SPRING-2 | | SINGLE | |
|---|---|---|---|------------------------------------|
| | Dolutegravir 50 mg Once Daily + 2 NRTIs (n = 403) | Raltegravir 400 mg Twice Daily + 2 NRTIs (n = 405) | Dolutegravir 50 mg + EPZICOM Once Daily (n = 414) | ATRIPLA Once Daily (n = 419) |
| Psychiatric | | | | |
| Insomnia | <1% | <1% | 3% | 3% |
| Depression | <1% | <1% | 1% | 2% |
| Abnormal dreams | <1% | <1% | <1% | 2% |
| Nervous System | | | | |
| Dizziness | <1% | <1% | <1% | 5% |
| Headache | <1% | <1% | 2% | 2% |
| Gastrointestinal | | | | |
| Nausea | 1% | 1% | <1% | 3% |
| Diarrhea | <1% | <1% | <1% | 2% |
| Skin and Subcutaneous Tissue | | | | |
| Rash ^a | 0 | <1% | <1% | 6% |
| General Disorders | | | | |
| Fatigue | <1% | <1% | 2% | 2% |
| Ear and Labyrinth | | | | |
| Vertigo | 0 | <1% | 0 | 2% |

^a Includes pooled terms: rash, rash generalized, rash macular, rash maculo-papular, rash pruritic, and drug eruption.

In addition, Grade 1 insomnia was reported by 1% and less than 1% of subjects receiving Dolutegravir 50mg tablets and raltegravir, respectively, in SPRING-2; whereas in SINGLE the rates were 7% and 4% for Dolutegravir 50mg tablets and ATRIPLA, respectively. These events were not treatment limiting.

In a multicenter, open-label trial (FLAMINGO), 243 subjects received Dolutegravir 50mg tablets once daily versus 242 subjects who received darunavir 800 mg/ritonavir 100 mg once daily, both in combination with investigator-selected NRTI background regimen (either EPZICOM or TRUVADA). There were 484 subjects included in the efficacy and safety analyses. Through 96 weeks, the rates of adverse events leading to discontinuation were 3% in subjects receiving Dolutegravir 50mg tablets and 6% in subjects receiving darunavir/ritonavir. The adverse reactions observed in FLAMINGO were generally consistent with those seen in SPRING-2 and SINGLE.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Naïve Subjects: In an international, multicenter, double-blind trial (ING111762, SAILING), 719 HIV-1–infected, antiretroviral treatment-experienced adults were randomized and received either Dolutegravir 50mg tablets once daily or raltegravir 400 mg twice daily with investigator-selected background regimen consisting of up to 2 agents, including at least one fully active agent. At 48 weeks, the rates of adverse events leading to discontinuation were 3% in subjects receiving Dolutegravir 50mg tablets once daily + background regimen and 4% in subjects receiving raltegravir 400 mg twice daily + background regimen.

The only treatment-emergent adverse reaction of moderate to severe intensity with at least 2% frequency in either treatment group was diarrhea, 2% (6 of 354) in subjects receiving Dolutegravir 50mg tablets once daily + background regimen and 1% (5 of 361) in subjects receiving raltegravir 400 mg twice daily + background regimen.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Experienced Subjects: In a multicenter, open-label, single-arm trial (ING112574, VIKING-3), 183 HIV-1–infected, antiretroviral treatment-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received Dolutegravir 50mg tablets twice daily with the current failing background regimen for 7 days and with optimized background therapy from Day 8. The rate of adverse events leading to discontinuation was 4% of subjects at Week 48.

Treatment-emergent adverse reactions in VIKING-3 were generally similar compared with observations with the 50-mg once-daily dose in adult Phase 3 trials.

Virologically Suppressed Subjects: The adverse reactions observed for Dolutegravir 50mg tablets plus rilpivirine in the Week 48 analysis of pooled data from 2 identical, international, multicenter, open-label trials (SWORD-1 and SWORD-2) of 513 HIV-1–infected, virologically suppressed subjects switching from their current antiretroviral regimen to dolutegravir plus rilpivirine, were consistent with the adverse reaction profiles and severities for the individual components when administered with other antiretroviral agents. There were no adverse reactions (Grades 2 to 4) with an incidence of at least 2% in either treatment arm. The rates of adverse events leading to discontinuation were 4% in subjects receiving Dolutegravir 50mg tablets plus rilpivirine once daily and less than 1% in subjects who remained on their current antiretroviral regimen.

Less Common Adverse Reactions Observed in Treatment-Naïve and Treatment-Experienced Trials: The following adverse reactions occurred in less than 2% of treatment-naïve or treatment-experienced subjects receiving Dolutegravir 50mg tablets in a combination regimen in any one trial. These events have been included because of their seriousness and assessment of potential causal relationship.

Gastrointestinal Disorders: Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.

Hepatobiliary Disorders: Hepatitis.

Musculoskeletal Disorders: Myositis.

Psychiatric Disorders: Suicidal ideation, attempt, behavior, or completion. These events were observed primarily in subjects with a pre-existing history of depression or other psychiatric illness.

Renal and Urinary Disorders: Renal impairment.

Skin and Subcutaneous Tissue Disorders: Pruritus.

Laboratory Abnormalities:

Treatment-Naïve Subjects: Selected laboratory abnormalities (Grades 2 to 4) with a worsening grade from baseline and representing the worst-grade toxicity in at least 2% of subjects are presented in Table 5. The mean change from baseline observed for selected lipid values is presented in Table 6. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.

Table 5. Selected Laboratory Abnormalities (Grades 2 to 4) in Treatment-Naïve Subjects in SPRING-2 (Week 96 Analysis) and SINGLE Trials (Week 144 Analysis)

| Laboratory Parameter Preferred Term | SPRING-2 | | SINGLE | |
|---|---|--|---|------------------------------|
| | Dolutegravir 50 mg Once Daily + 2 NRTIs (n = 403) | Raltegravir 400 mg Twice Daily + 2 NRTIs (n = 405) | Dolutegravir 50 mg + EPZICOM Once Daily (n = 414) | ATRIPLA Once Daily (n = 419) |
| ALT | | | | |
| Grade 2 (>2.5-5.0 x ULN) | 4% | 4% | 3% | 5% |
| Grade 3 to 4 (>5.0 x ULN) | 2% | 2% | 1% | <1% |
| AST | | | | |
| Grade 2 (>2.5-5.0 x ULN) | 5% | 3% | 3% | 4% |
| Grade 3 to 4 (>5.0 x ULN) | 3% | 2% | 1% | 3% |
| Total Bilirubin | | | | |
| Grade 2 (1.6-2.5 x ULN) | 3% | 2% | <1% | <1% |
| Grade 3 to 4 (>2.5 x ULN) | <1% | <1% | <1% | <1% |
| Creatine kinase | | | | |
| Grade 2 (6.0-9.9 x ULN) | 2% | 5% | 5% | 3% |
| Grade 3 to 4 (≥10.0 x ULN) | 7% | 4% | 7% | 8% |
| Hyperglycemia | | | | |
| Grade 2 (126-250 mg/dL) | 6% | 6% | 9% | 6% |
| Grade 3 (>250 mg/dL) | <1% | 2% | 2% | <1% |
| Lipase | | | | |
| Grade 2 (>1.5-3.0 x ULN) | 7% | 7% | 11% | 11% |
| Grade 3 to 4 (>3.0 x ULN) | 2% | 5% | 5% | 4% |
| Total neutrophils | | | | |
| Grade 2 (0.75-0.99 x 10 ⁹) | 4% | 3% | 4% | 5% |
| Grade 3 to 4 (<0.75 x 10 ⁹) | 2% | 2% | 3% | 3% |

ULN = Upper limit of normal.

Table 6. Mean Change from Baseline in Fasted Lipid Values in Treatment-Naïve Subjects in SPRING-2 (Week 96 Analysis^a) and SINGLE Trials (Week 144 Analysis^a)

| Laboratory Parameter Preferred Term | SPRING-2 | | SINGLE | |
|-------------------------------------|---|--|--|------------------------------|
| | Dolutegravir 50 mg Once Daily + 2 NRTIs (n = 403) | Raltegravir 400 mg Twice Daily + 2 NRTIs (n = 405) | Dolutegravir 50mg + EPZICOM Once Daily (n = 414) | ATRIPLA Once Daily (n = 419) |
| Cholesterol (mg/dL) | 8.1 | 10.1 | 24.0 | 26.7 |
| HDL cholesterol (mg/dL) | 2.0 | 2.3 | 5.4 | 7.2 |
| LDL cholesterol (mg/dL) | 5.1 | 6.1 | 16.0 | 14.6 |
| Triglycerides (mg/dL) | 6.7 | 6.6 | 13.6 | 31.9 |

^a Subjects on lipid-lowering agents at baseline were excluded from these analyses (19 subjects in each arm in SPRING-2, and in SINGLE: Dolutegravir 50mg tablets + EPZICOM n = 30 and ATRIPLA n = 27). Ninety-four subjects initiated a lipid-lowering agent post-baseline; their last fasted on-treatment values (prior to starting

the agent) were used regardless if they discontinued the agent (SPRING-2: Dolutegravir 50mg tablets n = 9, raltegravir n = 13; SINGLE: Dolutegravir 50mg tablets + EPZICOM n = 36, ATRIPLA n = 36).

Laboratory abnormalities observed in the FLAMINGO trial were generally consistent with observations in SPRING-2 and SINGLE.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Naïve Subjects: Laboratory abnormalities observed in SAILING were generally similar compared with observations seen in the treatment-naïve (SPRING-2 and SINGLE) trials.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Experienced Subjects: The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%). Two percent (4 of 183) of subjects had a Grade 3 to 4 treatment-emergent hematology laboratory abnormality, with neutropenia (2% [3 of 183]) being the most frequently reported.

Virologically Suppressed Adults: Laboratory abnormalities observed in SWORD-1 and SWORD-2 were generally similar compared with observations seen in the other Phase 3 trials.

Hepatitis B and/or Hepatitis C Virus Co-infection: In Phase 3 trials, subjects with hepatitis B and/or C virus co-infection were permitted to enroll provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal. Overall, the safety profile in subjects with hepatitis B and/or C virus co-infection was similar to that observed in subjects without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C virus co-infection for all treatment groups. Grades 2 to 4 ALT abnormalities in hepatitis B and/or C co-infected compared with HIV mono-infected subjects receiving Dolutegravir 50mg tablets were observed in 18% vs. 3% with the 50-mg once-daily dose and 13% vs. 8% with the 50-mg twice-daily dose. Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some subjects with hepatitis B and/or C at the start of therapy with Dolutegravir 50mg tablets, particularly in the setting where anti-hepatitis therapy was withdrawn [see 4.4]].

Changes in Serum Creatinine: Dolutegravir has been shown to increase serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function [see 5.1]]. Increases in serum creatinine occurred within the first 4 weeks of treatment and remained stable through 96 weeks. In treatment-naïve subjects, a mean change from baseline of 0.15 mg per dL (range: -0.32 mg per dL to 0.65 mg per dL) was observed after 96 weeks of treatment. Creatinine increases were comparable by background NRTIs and were similar in treatment-experienced subjects.

Clinical Trials Experience in Pediatric Subjects

The safety and pharmacokinetics of Dolutegravir 50mg tablets and Dolutegravir Dispersible Tablets 10 mg in HIV-1-infected pediatric subjects aged at least 4 weeks and weighing at least 3 kg was evaluated in the IMPAACT P1093 trial and 2 weight-band-based pharmacokinetic substudies of the ODYSSEY trial [], 5.2]. Overall, the safety data in these pediatric studies were similar to those seen in adults, and there was no clinically significant difference in dolutegravir exposure [see 5.2].

IMPAACT P1093 is an ongoing, multicenter, open-label, non-comparative trial of HIV-1-infected pediatric subjects aged 4 weeks to less than 18 years [see 5.2]].

The safety analysis based on subjects (n = 75) who received the recommended dose (determined by weight and age) through Week 24 showed that 11% of subjects experienced drug-related clinical adverse reactions. The only Grade 1 to 2 drug-related clinical adverse reactions reported by more than one subject was immune reconstitution inflammatory syndrome (IRIS) (n = 2). There were no Grade 3 or 4 drug-related adverse reactions reported. No adverse reactions led to discontinuation.

The Grade 3 or 4 laboratory abnormalities reported in more than one subject were decreased neutrophil count (n = 11), decreased blood bicarbonate (n = 4), decreased hemoglobin (n = 3), increased lipase (n = 2),

and increased blood potassium (n = 2). These laboratory events were not considered to be drug-related. Median laboratory values were similar at baseline and Week 24. Changes in median serum creatinine were similar to those observed in adults.

Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postmarketing use. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hepatobiliary Disorders

Acute liver failure, hepatotoxicity.

Investigations

Weight increased.

Musculoskeletal

Arthralgia, myalgia.

Psychiatric

Anxiety

4.9 Overdose

There is no known specific treatment for overdose with Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg. If overdose occurs, the patient should be monitored, and standard supportive treatment applied as required. As dolutegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antivirals for systemic use, other antivirals, ATC code: J05AX12

Namibia Pharmacological classification : 20.2.8 Antiviral agents

Mechanism of Action

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Strand transfer biochemical assays using purified HIV-1 integrase and pre-processed substrate DNA resulted in IC₅₀ values of 2.7 nM and 12.6 nM.

Antiviral Activity in Cell Culture

Dolutegravir exhibited antiviral activity against laboratory strains of wild-type HIV-1 with mean EC₅₀ values of 0.5 nM (0.21 ng per mL) to 2.1 nM (0.85 ng per mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells. Dolutegravir exhibited antiviral activity against 13 clinically diverse clade B isolates with a mean EC₅₀ value of 0.52 nM in a viral integrase susceptibility assay using the integrase coding region from clinical isolates. Dolutegravir demonstrated antiviral activity in cell culture against a panel of HIV-1 clinical isolates (3 in each group of M clades A, B, C, D, E, F, and G, and 3 in group O) with EC₅₀ values ranging from 0.02 nM to 2.14 nM

for HIV-1. Dolutegravir EC₅₀ values against 3 HIV-2 clinical isolates in PBMC assays ranged from 0.09 nM to 0.61 nM.

Antiviral Activity in Combination with Other Antiviral Agents

The antiviral activity of dolutegravir was not antagonistic when combined with the INSTI, raltegravir; non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz or nevirapine; the NRTIs, abacavir or stavudine; the protease inhibitors (PIs), amprenavir or lopinavir; the CCR5 co-receptor antagonist, maraviroc; or the fusion inhibitor, enfuvirtide. Dolutegravir antiviral activity was not antagonistic when combined with the HBV reverse transcriptase inhibitor, adefovir, or inhibited by the antiviral, ribavirin.

Resistance

Cell Culture: Dolutegravir-resistant viruses were selected in cell culture starting from different wild-type HIV-1 strains and clades. Amino acid substitutions E92Q, G118R, S153F or Y, G193E or R263K emerged in different passages and conferred decreased susceptibility to dolutegravir of up to 4-fold. Passage of mutant viruses containing the Q148R or Q148H substitutions selected for additional substitutions in integrase that conferred decreased susceptibility to dolutegravir (fold-change increase of 13 to 46). The additional integrase substitutions included T97A, E138K, G140S, and M154I. Passage of mutant viruses containing both G140S and Q148H selected for L74M, E92Q, and N155H.

Treatment-Naïve Subjects: No subject who received dolutegravir 50-mg once-daily in the treatment-naïve trials SPRING-2 (96 weeks) and SINGLE (144 weeks) had a detectable decrease in susceptibility to dolutegravir or background NRTIs in the resistance analysis subset (n = 12 with HIV-1 RNA greater than 400 copies per mL at failure or last visit and having resistance data). Two virologic failure subjects in SINGLE had treatment-emergent G/D/E193D and G193G/E integrase substitutions at Week 84 and Week 108, respectively, and 1 subject with 275 copies per mL HIV-1 RNA had a treatment-emergent Q157Q/P integrase substitution detected at Week 24. None of these subjects had a corresponding decrease in dolutegravir susceptibility. No treatment-emergent genotypic resistance to the background regimen was observed in the dolutegravir arm in either the SPRING-2 or SINGLE trials. No treatment-emergent primary resistance substitutions were observed in either treatment group in the FLAMINGO trial through Week 96.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Naïve Subjects: In the dolutegravir arm of the SAILING trial for treatment-experienced and INSTI-naïve subjects (n = 354), treatment-emergent integrase substitutions were observed in 6 of 28 (21%) subjects who had virologic failure and resistance data. In 5 of the 6 subjects' isolates emergent INSTI substitutions included L74L/M/I, Q95Q/L, V151V/I (n = 1 each), and R263K (n = 2). The change in dolutegravir phenotypic susceptibility for these 5 subject isolates was less than 2-fold. One subject isolate had pre-existing raltegravir resistance substitutions E138A, G140S, and Q148H at baseline and had additional emergent INSTI-resistance substitutions T97A and E138A/T with a corresponding 148-fold reduction in dolutegravir susceptibility at failure. In the comparator raltegravir arm, 21 of 49 (43%) subjects with post-baseline resistance data had evidence of emergent INSTI-resistance substitutions (L74M, E92Q, T97A, E138Q, G140S/A, Y143R/C, Q148H/R, V151I, N155H, E157Q, and G163K/R) and raltegravir phenotypic resistance.

Virologically Suppressed Subjects: SWORD-1 and SWORD-2 are identical trials in virologically suppressed subjects receiving 2 NRTIs plus either an INSTI, an NNRTI, or a PI, that switched to dolutegravir plus rilpivirine (n = 513) or remained on their current antiviral regimen (n = 511). Two subjects in each treatment arm had confirmed virologic failure at any time through Week 48. The 2 subjects in the dolutegravir/rilpivirine arm had detectable resistance substitutions at rebound. One subject had the NNRTI-resistance-associated substitution K101K/E with no decreased susceptibility to rilpivirine (fold-change = 1.2) at Week 36, had no INSTI resistance-associated substitutions or decreased susceptibility to dolutegravir (fold-change less than 2), and had HIV-1 RNA less than 50 copies per mL at the withdrawal visit. The other subject had the dolutegravir resistance-associated substitution G193E at baseline (by exploratory HIV proviral DNA archive sequencing) and at Week 24 (by conventional sequencing) without decreased susceptibility to dolutegravir (fold-change = 1.02) at Week 24. No resistance-associated substitutions were observed for the other 2 subjects in the comparative current antiretroviral regimen arm.

Treatment-Experienced, Integrase Strand Transfer Inhibitor-Experienced Subjects: VIKING-3 examined the efficacy of dolutegravir 50 mg twice daily plus optimized background therapy in subjects with prior or current virologic failure on an INSTI- (elvitegravir or raltegravir) containing regimen. Use of Dolutegravir 50mg tablets in INSTI-experienced patients should be guided by the number and type of baseline INSTI substitutions. The efficacy of Dolutegravir 50mg tablets twice daily is reduced in patients with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions, including T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R.

Response by Baseline Genotype

Of the 183 subjects with baseline data, 30% harbored virus with a substitution at Q148, and 33% had no primary INSTI-resistance substitutions (T66A/I/K, E92Q/V, Y143R/C/H, Q148H/R/K, and N155H) at baseline, but had historical genotypic evidence of INSTI-resistance substitutions, phenotypic evidence of elvitegravir or raltegravir resistance, or genotypic evidence of INSTI-resistance substitutions at screening.

Response rates by baseline genotype were analyzed in an “as-treated” analysis at Week 48 (n = 175) (Table 7). The response rate at Week 48 to dolutegravir-containing regimens was 47% (24 of 51) when Q148 substitutions were present at baseline; Q148 was always present with additional INSTI-resistance substitutions (Table 7). In addition, a diminished virologic response of 40% (6 of 15) was observed when the substitution E157Q or K was present at baseline with other INSTI-resistance substitutions but without a Q148H or R substitution.

Table 7. Response by Baseline Integrase Genotype in Subjects with Prior Experience to an Integrase Strand Transfer Inhibitor in VIKING-3

| Baseline Genotype | Week 48 (<50 copies/mL) n = 175 |
|---|---|
| Overall Response | 66% (116/175) |
| No Q148 substitution ^a | 74% (92/124) |
| Q148H/R + G140S/A/C without additional INSTI-resistance substitution ^b | 61% (17/28) |
| Q148H/R + ≥2 INSTI-resistance substitutions ^{b,c} | 29% (6/21) |

^a Includes INSTI-resistance substitutions Y143R/C/H and N155H.

^b INSTI-resistance substitutions included T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R. Two additional subjects had baseline genotypes of Q148Q/R plus L74L/I/M (virologic failure) and Q148R plus E138K (responder).

^c The most common pathway with Q148H/R + greater than or equal to 2 INSTI-resistance substitutions had Q148+G140+E138 substitutions (n = 16).

Response by Baseline Phenotype

Response rates by baseline phenotype were analyzed in an as-treated analysis using all subjects with available baseline phenotypes through Week 48 (n = 163) (Table 8). These baseline phenotypic groups are based on subjects enrolled in VIKING-3 and are not meant to represent definitive clinical susceptibility cut points for dolutegravir. The data are provided to guide clinicians on the likelihood of virologic success based on pretreatment susceptibility to dolutegravir in INSTI-resistant patients.

Table 8. Response by Baseline Dolutegravir Phenotype (Fold-Change from Reference) in Subjects with Prior Experience to an Integrase Strand Transfer Inhibitor in VIKING-3

| Baseline Dolutegravir Phenotype (Fold-Change from Reference) | Response at Week 48 (<50 copies/mL) Subset n = 163 |
|---|--|
| Overall Response | 64% (104/163) |
| <3-fold change | 72% (83/116) |
| 3- <10-fold change | 53% (18/34) |
| ≥10-fold change | 23% (3/13) |

Integrase Strand Transfer Inhibitor Treatment-Emergent Resistance

There were 50 subjects with virologic failure on the dolutegravir twice-daily regimen in VIKING-3 with HIV-1 RNA greater than 400 copies per mL at the failure timepoint, Week 48 or beyond, or the last timepoint on trial. Thirty-nine subjects with virologic failure had resistance data that were used in the Week 48 analysis. In the Week 48 resistance analysis 85% (33 of 39) of the subjects with virologic failure had treatment-emergent INSTI-resistance substitutions in their isolates. The most common treatment-emergent INSTI-resistance substitution was T97A. Other frequently emergent INSTI-resistance substitutions included L74M, I or V, E138K or A, G140S, Q148H, R or K, M154I, or N155H. Substitutions E92Q, Y143R or C/H, S147G, V151A, and E157E/Q each emerged in 1 to 3 subjects' isolates. At failure, the median dolutegravir fold-change from reference was 61-fold (range: 0.75 to 209) for isolates with emergent INSTI-resistance substitutions (n = 33).

Resistance to one or more background drugs in the dolutegravir twice-daily regimen also emerged in 49% (19 of 39) of subjects in the Week 48 resistance analysis.

In VIKING-4 (ING116529), 30 subjects with current virological failure on an INSTI-containing regimen and genotypic evidence of INSTI-resistance substitutions at screening were randomized to receive either dolutegravir 50 mg twice daily or placebo with the current failing regimen for 7 days and then all subjects received open-label dolutegravir plus optimized background regimen from Day 8. Virologic responses at Week 48 by baseline genotypic and phenotypic INSTI-resistance categories and the INSTI resistance-associated substitutions that emerged on dolutegravir treatment in VIKING-4 were consistent with those seen in VIKING-3.

Cross-Resistance

Site-Directed Integrase Strand Transfer Inhibitor-Resistant Mutant HIV-1 and HIV-2 Strains: The susceptibility of dolutegravir was tested against 60 INSTI-resistant site-directed mutant HIV-1 viruses (28 with single substitutions and 32 with 2 or more substitutions) and 6 INSTI-resistant site-directed mutant HIV-2 viruses. The single INSTI-resistance substitutions T66K, I151L, and S153Y conferred a greater than 2-fold decrease in dolutegravir susceptibility (range: 2.3-fold to 3.6-fold from reference). Combinations of multiple substitutions T66K/L74M, E92Q/N155H, G140C/Q148R, G140S/Q148H, R or K, Q148R/N155H, T97A/G140S/Q148, and substitutions at E138/G140/Q148 showed a greater than 2-fold decrease in dolutegravir susceptibility (range: 2.5-fold to 21-fold from reference). In HIV-2 mutants, combinations of substitutions A153G/N155H/S163G and E92Q/T97A/N155H/S163D conferred 4-fold decreases in dolutegravir susceptibility, and E92Q/N155H and G140S/Q148R showed 8.5-fold and 17-fold decreases in dolutegravir susceptibility, respectively.

Reverse Transcriptase Inhibitor- and Protease Inhibitor-Resistant Strains: Dolutegravir demonstrated equivalent antiviral activity against 2 NNRTI-resistant, 3 NRTI-resistant, and 2 PI-resistant HIV-1 mutant clones compared with the wild-type strain.

Pharmacodynamics

Effects on Electrocardiogram

In a randomized, placebo-controlled, cross-over trial, 42 healthy subjects received single-dose oral administrations of placebo, dolutegravir 250-mg suspension (exposures approximately 3-fold of the 50-mg

once-daily dose at steady state), and moxifloxacin 400 mg (active control) in random sequence. After baseline and placebo adjustment, the maximum mean QTc change based on Fridericia correction method (QTcF) for dolutegravir was 2.4 msec (1-sided 95% upper CI: 4.9 msec). Dolutegravir did not prolong the QTc interval over 24 hours postdose.

Effects on Renal Function

The effect of dolutegravir on renal function was evaluated in an open-label, randomized, 3-arm, parallel, placebo-controlled trial in healthy subjects (n = 37) who received dolutegravir 50 mg once daily (n = 12), dolutegravir 50 mg twice daily (n = 13), or placebo once daily (n = 12) for 14 days. A decrease in creatinine clearance, as determined by 24-hour urine collection, was observed with both doses of dolutegravir after 14 days of treatment in subjects who received 50 mg once daily (9% decrease) and 50 mg twice daily (13% decrease). Neither dose of dolutegravir had a significant effect on the actual glomerular filtration rate (determined by the clearance of probe drug, iohexol) or effective renal plasma flow (determined by the clearance of probe drug, para-amino hippurate) compared with the placebo.

5.2 Pharmacokinetic properties

Pharmacokinetics

The pharmacokinetic properties of dolutegravir have been evaluated in healthy adult subjects and HIV-1–infected adult subjects. Exposure to dolutegravir was generally similar between healthy subjects and HIV-1–infected subjects. The non-linear exposure of dolutegravir following 50 mg twice daily compared with 50 mg once daily in HIV-1–infected subjects (Table 9) was attributed to the use of metabolic inducers in the background antiretroviral regimens of subjects receiving dolutegravir 50 mg twice daily in clinical trials.

Table 9. Dolutegravir Steady-State Pharmacokinetic Parameter Estimates in HIV-1–Infected Adults

| Parameter | 50 mg Once Daily Geometric Mean ^a (%CV) | 50 mg Twice Daily Geometric Mean ^b (%CV) |
|----------------------------------|---|--|
| AUC ₍₀₋₂₄₎ (mcg.h/mL) | 53.6 (27) | 75.1 (35) |
| C _{max} (mcg/mL) | 3.67 (20) | 4.15 (29) |
| C _{min} (mcg/mL) | 1.11 (46) | 2.12 (47) |

^a Based on population pharmacokinetic analyses using data from SPRING-1 and SPRING-2.

^b Based on population pharmacokinetic analyses using data from VIKING (ING112961) and VIKING-3.

Dolutegravir 50mg tablets and Dolutegravir Dispersible Tablets 10 mg tablets for oral suspension are not bioequivalent. The relative bioavailability of Dolutegravir Dispersible Tablets 10 mg is approximately 1.6-fold higher than Dolutegravir 50mg tablets; therefore, the 2 dosage forms are not interchangeable on a milligram-per-milligram basis [see *Dosage and Administration (2.3)*].

Absorption

Following oral administration of dolutegravir, peak plasma concentrations were observed 2 to 3 hours postdose. With once-daily dosing, pharmacokinetic steady state is achieved within approximately 5 days with average accumulation ratios for AUC, C_{max}, and C_{24 h} ranging from 1.2 to 1.5.

Dolutegravir plasma concentrations increased in a less than dose-proportional manner above 50 mg. Dolutegravir is a P-gp substrate in vitro. The absolute bioavailability of dolutegravir has not been established.

Effect of Food: Dolutegravir 50mg tablets or Dolutegravir Dispersible Tablets 10 mg may be taken with or without food. Food increased the extent of absorption and slowed the rate of absorption of dolutegravir

following a 50-mg dose of Dolutegravir 50mg . Low-, moderate-, and high-fat meals increased dolutegravir AUC_(0-∞) by 33%, 41%, and 66%; increased C_{max} by 46%, 52%, and 67%; and prolonged T_{max} to 3, 4, and 5 hours from 2 hours under fasted conditions, respectively.

Distribution

Dolutegravir is highly bound (greater than or equal to 98.9%) to human plasma proteins based on in vivo data and binding is independent of plasma concentration of dolutegravir. The apparent volume of distribution (Vd/F) following 50-mg once-daily administration is estimated at 17.4 L based on a population pharmacokinetic analysis.

Cerebrospinal Fluid (CSF): In 12 treatment-naïve subjects on dolutegravir 50 mg daily plus abacavir/lamivudine, the median dolutegravir concentration in CSF was 13.2 ng per mL (range: 3.74 ng per mL to 18.3 ng per mL) 2 to 6 hours postdose after 16 weeks of treatment. The clinical relevance of this finding has not been established.

Elimination

Dolutegravir has a terminal half-life of approximately 14 hours and an apparent clearance (CL/F) of 1.0 L per hour based on population pharmacokinetic analyses.

Metabolism: Dolutegravir is primarily metabolized via UGT1A1 with some contribution from CYP3A.

Polymorphisms in Drug-Metabolizing Enzymes: In a meta-analysis of healthy subject trials, subjects with UGT1A1 (n = 7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n = 41).

Excretion: After a single oral dose of [¹⁴C] dolutegravir, 53% of the total oral dose was excreted unchanged in feces. Thirty-one percent of the total oral dose was excreted in urine, represented by an ether glucuronide of dolutegravir (18.9% of total dose), a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose), and its hydrolytic N-dealkylation product (3.6% of total dose). Renal elimination of unchanged drug was low (less than 1% of the dose).

Specific Populations

Pediatric Patients: The pharmacokinetics of dolutegravir were evaluated in the IMPAACT P1093 trial and in 2 weight-band-based pharmacokinetic substudies from the ODYSSEY trial. Steady-state plasma exposure at doses by weight band are summarized in Table 10

Mean dolutegravir AUC_{0-24h} and C_{24h} in HIV-1–infected pediatric subjects were comparable to those in adults after 50 mg once daily or 50 mg twice daily. Mean C_{max} is higher in pediatrics, but the increase is not considered clinically significant as the safety profiles were similar in pediatric and adult subjects [see 4,2)].

Table 10. Summary of Pharmacokinetic Parameters in Pediatric HIV-1–Infected Subjects (Pooled Analyses for IMPAACT P1093 and ODYSSEY^a Trials)

| Weight Band | Dose ^b of Dolutegravir tablets or Dolutegravir Dispersible Tablets | n | Pharmacokinetic Parameter Geometric Mean (%CV) | | |
|----------------|---|----|--|---------------------------------|--------------------------|
| | | | C _{max} (mcg/mL) | AUC _{0-24h} (mcg·h/mL) | C _{24h} (ng/mL) |
| 3 kg to <6 kg | Dolutegravir Dispersible Tablets 5 mg once daily | 8 | 3.80 (34) | 49.37 (49) | 962 (98) |
| 6 kg to <10 kg | Dolutegravir Dispersible Tablets 15 mg once daily | 17 | 5.27 (50) | 57.17 (76) | 706 (177) |

| | | | | | |
|-----------------|--|----|-----------|------------|-----------|
| 10 kg to <14 kg | Dolutegravir Dispersible Tablets Dolutegravir Dispersible Tablets 20 mg once daily | 13 | 5.99 (33) | 68.75 (48) | 977 (100) |
| 14 kg to <20 kg | Dolutegravir Dispersible Tablets 25 mg once daily | 19 | 5.97 (42) | 58.97 (44) | 725 (75) |
| 20 kg to <25 kg | Dolutegravir Dispersible Tablets 30 mg once daily | 9 | 7.16 (26) | 71.53 (26) | 759 (73) |
| ≥20 kg | Dolutegravir Tablets 50 mg once daily | 49 | 4.92 (40) | 54.98 (43) | 778 (62) |

^a Data from 2 weight-band-based pharmacokinetic substudies in the ODYSSEY trial.

^b The bioavailability of Dolutegravir tablets for oral suspension is ~1.6-fold that of Dolutegravir tablets.

Patients with Hepatic Impairment: In a trial comparing 8 subjects with moderate hepatic impairment (Child-Pugh Score B) with 8 matched healthy controls, exposure of dolutegravir from a single 50-mg dose was similar between the 2 groups. The effect of severe hepatic impairment (Child-Pugh Score C) on the pharmacokinetics of dolutegravir has not been studied.

Patients with Renal Impairment: In a trial evaluating the pharmacokinetics of a single 50-mg tablet of dolutegravir comparing 8 subjects with severe renal impairment (CrCl less than 30 mL per min) with 8 matched healthy controls, AUC, C_{max}, and C₂₄ of dolutegravir were lower by 40%, 23%, and 43%, respectively, compared with those in matched healthy subjects. Population pharmacokinetic analysis using data from SAILING and VIKING-3 trials indicated that mild and moderate renal impairment had no clinically relevant effect on the exposure of dolutegravir. There is inadequate information to recommend appropriate dosing of dolutegravir in patients requiring dialysis.

HBV or HCV Co-infected Patients: Population analyses using pooled pharmacokinetic data from adult trials indicated no clinically relevant effect of HCV co-infection on the pharmacokinetics of dolutegravir. There were limited data on HBV co-infection.

Gender and Race: Population analyses using pooled pharmacokinetic data from adult trials indicated gender and race had no clinically relevant effect on the exposure of dolutegravir.

Drug Interaction Studies

Drug interaction trials were performed with Dolutegravir tablets and other drugs likely to be coadministered or commonly used as probes for pharmacokinetic interactions. The effects of dolutegravir on the exposure of coadministered drugs are summarized in Table 11 and the effects of coadministered drugs on the exposure of dolutegravir are summarized in Table 12.

Dosing or regimen recommendations as a result of established and other potentially significant drug-drug interactions with Dolutegravir tablets are provided in Table 3 [see *Dosage and Administration* (42), (4.5)].

Table 11. Summary of Effect of Dolutegravir on the Pharmacokinetics of Coadministered Drugs

| Coadministered Drug(s) and Dose(s) | Dose of Dolutegravir tablets | n | Geometric Mean Ratio (90% CI) of Pharmacokinetic Parameters of Coadministered Drug with/without Dolutegravir No Effect = 1.00 | | |
|---|------------------------------------|-----------------|--|--|-----------------------------------|
| | | | C _{max} | AUC | C _r or C ₂₄ |
| Daclatasvir 60 mg once daily | 50 mg once daily | 12 | 1.03 (0.84 to 1.25) | 0.98 (0.83 to 1.15) | 1.06 (0.88 to 1.29) |
| Elbasvir 50 mg once daily | 50 mg single dose | 12 | 0.97 (0.89, 1.05) | 0.98 (0.93, 1.04) | 0.98 (0.93, 1.03) |
| Ethinyl estradiol 0.035 mg | 50 mg twice daily | 15 | 0.99 (0.91 to 1.08) | 1.03 (0.96 to 1.11) | 1.02 (0.93 to 1.11) |
| Grazoprevir 200 mg once daily | 50 mg single dose | 12 | 0.64 (0.44, 0.93) | 0.81 (0.67, 0.97) | 0.86 (0.79, 0.93) |
| Metformin 500 mg twice daily | 50 mg once daily | 15 ^a | 1.66 (1.53 to 1.81) | 1.79 (1.65 to 1.93) | – |
| Metformin 500 mg twice daily | 50 mg twice daily | 15 ^a | 2.11 (1.91 to 2.33) | 2.45 (2.25 to 2.66) | – |
| Methadone 16 to 150 mg | 50 mg twice daily | 11 | 1.00 (0.94 to 1.06) | 0.98 (0.91 to 1.06) | 0.99 (0.91 to 1.07) |
| Midazolam 3 mg | 25 mg once daily | 10 | – | 0.95 (0.79 to 1.15) | – |
| Norelgestromin 0.25 mg | 50 mg twice daily | 15 | 0.89 (0.82 to 0.97) | 0.98 (0.91 to 1.04) | 0.93 (0.85 to 1.03) |
| Rilpivirine 25 mg once daily | 50 mg once daily | 16 | 1.10 (0.99 to 1.22) | 1.06 (0.98 to 1.16) | 1.21 (1.07 to 1.38) |
| Sofosbuvir 400 mg once daily Metabolite (GS-331007) | 50 mg once daily | 24 | 0.88 (0.80, 0.98) 1.01 (0.93, 1.10) | 0.92 (0.85, 0.99) 0.99 (0.97, 1.01) | NA 0.99 (0.97, 1.01) |
| Tenofovir disoproxil fumarate 300 mg once daily | 50 mg once daily | 15 | 1.09 (0.97 to 1.23) | 1.12 (1.01 to 1.24) | 1.19 (1.04 to 1.35) |
| Velpatasvir 100 mg once daily | 50 mg once daily | 24 | 0.94 (0.86, 1.02) | 0.91 (0.84, 0.98) | 0.88 (0.82, 0.94) |

^a The number of subjects represents the maximum number of subjects that were evaluated.

Table 12. Summary of Effect of Coadministered Drugs on the Pharmacokinetics of Dolutegravir

| Coadministered Drug(s) and Dose(s) | Dose of Dolutegravir tablets | n | Geometric Mean Ratio (90% CI) of Dolutegravir Pharmacokinetic Parameters with/without Coadministered Drugs No Effect = 1.00 | | |
|---|------------------------------------|----|--|------------------------|-----------------------------------|
| | | | C _{max} | AUC | C _r or C ₂₄ |
| Atazanavir 400 mg once daily | 30 mg once daily | 12 | 1.50 (1.40 to 1.59) | 1.91 (1.80 to 2.03) | 2.80 (2.52 to 3.11) |
| Atazanavir/ritonavir 300/100 mg once daily | 30 mg once daily | 12 | 1.34 (1.25 to 1.42) | 1.62 (1.50 to 1.74) | 2.21 (1.97 to 2.47) |
| Darunavir/ritonavir 600/100 mg twice daily | 30 mg once daily | 15 | 0.89 (0.83 to 0.97) | 0.78 (0.72 to 0.85) | 0.62 (0.56 to 0.69) |
| Efavirenz 600 mg once daily | 50 mg once daily | 12 | 0.61 (0.51 to 0.73) | 0.43 (0.35 to 0.54) | 0.25 (0.18 to 0.34) |

| | | | | | |
|--|----------------------|-----------------|------------------------|------------------------|------------------------|
| Elbasvir/grazoprevir 50/200 mg once daily | 50 mg single dose | 12 | 1.22 (1.05, 1.40) | 1.16 (1.00, 1.34) | 1.14 (0.95, 1.36) |
| Etravirine 200 mg twice daily | 50 mg once daily | 16 | 0.48 (0.43 to 0.54) | 0.29 (0.26 to 0.34) | 0.12 (0.09 to 0.16) |
| Etravirine + darunavir/ritonavir 200 mg + 600/100 mg twice daily | 50 mg once daily | 9 | 0.88 (0.78 to 1.00) | 0.75 (0.69 to 0.81) | 0.63 (0.52 to 0.76) |
| Etravirine + lopinavir/ritonavir 200 mg + 400/100 mg twice daily | 50 mg once daily | 8 | 1.07 (1.02 to 1.13) | 1.11 (1.02 to 1.20) | 1.28 (1.13 to 1.45) |
| Fosamprenavir/ritonavir 700 mg/100 mg twice daily | 50 mg once daily | 12 | 0.76 (0.63 to 0.92) | 0.65 (0.54 to 0.78) | 0.51 (0.41 to 0.63) |
| Lopinavir/ritonavir 400/100 mg twice daily | 30 mg once daily | 15 | 1.00 (0.94 to 1.07) | 0.97 (0.91 to 1.04) | 0.94 (0.85 to 1.05) |
| Rilpivirine 25 mg once daily | 50 mg once daily | 16 | 1.13 (1.06 to 1.21) | 1.12 (1.05 to 1.19) | 1.22 (1.15 to 1.30) |
| Tenofovir 300 mg once daily | 50 mg once daily | 15 | 0.97 (0.87 to 1.08) | 1.01 (0.91 to 1.11) | 0.92 (0.82 to 1.04) |
| Tipranavir/ritonavir 500/200 mg twice daily | 50 mg once daily | 14 | 0.54 (0.50 to 0.57) | 0.41 (0.38 to 0.44) | 0.24 (0.21 to 0.27) |
| Antacid (MAALOX) simultaneous administration | 50 mg single dose | 16 | 0.28 (0.23 to 0.33) | 0.26 (0.22 to 0.32) | 0.26 (0.21 to 0.31) |
| Antacid (MAALOX) 2 h after dolutegravir | 50 mg single dose | 16 | 0.82 (0.69 to 0.98) | 0.74 (0.62 to 0.90) | 0.70 (0.58 to 0.85) |
| Calcium carbonate 1,200 mg simultaneous administration (fasted) | 50 mg single dose | 12 | 0.63 (0.50 to 0.81) | 0.61 (0.47 to 0.80) | 0.61 (0.47 to 0.80) |
| Calcium carbonate 1,200 mg simultaneous administration (fed) | 50 mg single dose | 11 | 1.07 (0.83 to 1.38) | 1.09 (0.84 to 1.43) | 1.08 (0.81 to 1.42) |
| Calcium carbonate 1,200 mg 2 h after dolutegravir | 50 mg single dose | 11 | 1.00 (0.78 to 1.29) | 0.94 (0.72 to 1.23) | 0.90 (0.68 to 1.19) |
| Carbamazepine 300 mg twice daily | 50 mg once daily | 16 ^c | 0.67 (0.61 to 0.73) | 0.51 (0.48 to 0.55) | 0.27 (0.24 to 0.31) |
| Daclatasvir 60 mg once daily | 50 mg once daily | 12 | 1.29 (1.07 to 1.57) | 1.33 (1.11 to 1.59) | 1.45 (1.25 to 1.68) |
| Ferrous fumarate 324 mg simultaneous administration (fasted) | 50 mg single dose | 11 | 0.43 (0.35 to 0.52) | 0.46 (0.38 to 0.56) | 0.44 (0.36 to 0.54) |
| Ferrous fumarate 324 mg simultaneous administration (fed) | 50 mg single dose | 11 | 1.03 (0.84 to 1.26) | 0.98 (0.81 to 1.20) | 1.00 (0.81 to 1.23) |
| Ferrous fumarate 324 mg 2 h after dolutegravir | 50 mg single dose | 10 | 0.99 (0.81 to 1.21) | 0.95 (0.77 to 1.15) | 0.92 (0.74 to 1.13) |
| Multivitamin (One-A-Day) simultaneous administration | 50 mg single dose | 16 | 0.65 (0.54 to 0.77) | 0.67 (0.55 to 0.81) | 0.68 (0.56 to 0.82) |
| Omeprazole 40 mg once daily | 50 mg single dose | 12 | 0.92 (0.75 to 1.11) | 0.97 (0.78 to 1.20) | 0.95 (0.75 to 1.21) |
| Prednisone 60 mg once daily with taper | 50 mg once daily | 12 | 1.06 (0.99 to 1.14) | 1.11 (1.03 to 1.20) | 1.17 (1.06 to 1.28) |

| | | | | | |
|--|----------------------|----|------------------------|------------------------|------------------------|
| Rifampin ^a 600 mg once daily | 50 mg twice daily | 11 | 0.57 (0.49 to 0.65) | 0.46 (0.38 to 0.55) | 0.28 (0.23 to 0.34) |
| Rifampin ^b 600 mg once daily | 50 mg twice daily | 11 | 1.18 (1.03 to 1.37) | 1.33 (1.15 to 1.53) | 1.22 (1.01 to 1.48) |
| Rifabutin 300 mg once daily | 50 mg once daily | 9 | 1.16 (0.98 to 1.37) | 0.95 (0.82 to 1.10) | 0.70 (0.57 to 0.87) |

^a Comparison is rifampin taken with dolutegravir 50 mg twice daily compared with dolutegravir 50 mg twice daily.

^b Comparison is rifampin taken with dolutegravir 50 mg twice daily compared with dolutegravir 50 mg once daily.

^c The number of subjects represents the maximum number of subjects that were evaluated.

5.3 Preclinical safety data

IMPAACT P1093 is an ongoing Phase 1/2, multicenter, open-label trial to evaluate the pharmacokinetic parameters, safety, tolerability, and efficacy of Dolutegravir tablets or Dolutegravir Dispersible Tablets in combination treatment regimens in HIV-1–infected infants, children, and adolescents aged at least 4 weeks to 18 years. Subjects were stratified by 5 age cohorts: Cohort 1, aged 12 to less than 18 years; Cohort 2A, aged 6 to less than 12 years; Cohort 3, aged 2 to less than 6 years; Cohort 4, aged 6 months to less than 2 years; and Cohort 5, aged 4 weeks to less than 6 months. Seventy-five subjects received the recommended dose (determined by weight and age) of Dolutegravir tablets or Dolutegravir Dispersible Tablets [see 4.2

These 75 subjects had a median age of 27 months (range: 1 to 214), were 59% female, and 68% were black or African American. At baseline, mean plasma HIV-1 RNA was 4.4 log₁₀ copies per mL, median CD4+ cell count was 1,225 cells per mm³ (range: 1 to 8,255), and median CD4+% was 23% (range: 0.3% to 49%). Overall, 33% had baseline plasma HIV-1 RNA greater than 50,000 copies per mL and 12% had a CDC HIV clinical classification of category C. The majority (80%) of subjects were treatment-experienced, but all were INSTI-naïve. Most subjects had previously used at least 1 NNRTI (44%) or 1 PI (76%).

Virologic outcomes from IMPAACT P1093 include subjects who received either Dolutegravir tablets or Dolutegravir Dispersible tablets for oral suspension as per the dosing recommendations for their weight band and who had reached Week 24 (n = 58) or Week 48 (n = 42). At Week 24, 62% of subjects achieved HIV-1 RNA less than 50 copies per mL and 86% achieved HIV-1 RNA less than 400 copies per mL (Snapshot algorithm). The median CD4 count (percent) increase from baseline to Week 24 was 105 cells per mm³ (5%). At Week 48, 69% of subjects achieved HIV-1 RNA less than 50 copies per /mL and 79% achieved HIV-1 RNA less than 400 copies per mL (Snapshot algorithm). The median CD4 count (percent) increase from baseline to Week 48 was 141 cells per mm³ (7%).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Core Tablet

Mannitol, Microcrystalline cellulose,
Sodium starch glycolate,
Povidone, Silicified Microcrystalline cellulose,
Crospovidone, Calcium Sulfate, Sucralose,
Strawberry Cream Flavor and Sodium Stearyl Fumarate.

Film Coat

Hypromellose,

Macrogol/polyethylene glycol,

titanium dioxide,

red iron oxide,

yellow iron oxide and black iron oxide.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 Months

6.4 Special precautions for storage

Do not store above 30°C. Store in the original container.

6.5 Nature and contents of container

HDPE Bottle pack of 30's, 60's, 90's,180's and 270's*

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements for disposal.

7. Mfg. by

Mylan Laboratories Limited,

Plot no: 11-12 & 13, Indore SEZ, Pharma Zone,

Phase-II, Sector-III, Pithampur – 454775

Dist. Dhar (MP) India.

8. Marketed by

Mylan Laboratories Limited, India.

Zambia Regn No.:

Zimbabwe Regn No.:

Botswana Regn No.:

Namibia Regn No.:

Namibia Scheduling Status.: NS2

References:-

1. **TIVICAY PD:** FDA- Labeling-Package Insert (ViiV Healthcare)- Reference ID: 4624117.
2. POLICY BRIEF — JULY 2020 -Considerations for introducing new antiretroviral drug formulations for children

**The Product has been produced under a licence from the Medicines Patent Pool.
The Product is not for administration to anyone other than Child Patients.
Any other use is not authorized.**